Shares in Bayer fell dramatically in the wake of a court ordering its unit Monsanto to pay out $289 million in damages in a cancer trial. (Photo: Mike Mozart/Flickr/cc)
Aug 13, 2018
Shares in Bayer took a nosedive on Monday--just days after newly-acquired Monsanto was ordered to pay $289 million in damages to a man who alleged that the company's glyphosate-based herbicides, including the widely used weedkiller Roundup, caused his cancer.
At one point the German pharmaceutical giant's shares fell by as much as 14 percent, Reutersreported, marking a loss in value of roughly $14 billion.
It capped off the U.S. trading day as one of the "biggest losers," ending at a 10-percent loss.
Friday was also a losing day for Monsanto, which Bayer AG controversially acquired for $62.5 billion in June. In a landmark trial, a San Francisco jury unanimously found that the company failed to warn school groundskeeper Dewayne Johnson, who's suffering from non-Hodgkin's lymphoma, and other consumers of the cancer risks from its weed killers, and said the company acted "with malice or oppression."
\u201cWith this verdict and more than 4,000 other plaintiffs waiting in the wings, @MonsantoCo could be in court for decades to come and it could cost them and its new owner, @Bayer, hundreds of millions \u2013 if not billions \u2013 of dollars in damages. #Rounduptrial https://t.co/3ZyGr0eWko\u201d— carey gillam \u270d\ufe0f \ud83d\udcd3 (@carey gillam \u270d\ufe0f \ud83d\udcd3) 1534182010
The International Agency for Research on Cancer (IARC)--a branch of the World Health Organization (WHO)--classified glyphosate as a probable human carcinogen, but Monsanto says its Roundup is safe, and that it plans on appealing.
Monday also marked the last day of the public comment period for the finalization of the merger process, prompting a broad range of advocacy groups to voice their opposition once again.
"No matter how you cut it," said said Daniel Raichel, an attorney with the Nature Program at NRDC, "a Bayer/Monsanto merger spells higher costs for farmers and locks in the chemical-heavy agricultural practices that threaten our health and the bees and other pollinators critical to food security."
"The Department needs to reverse course and block the merger before we all suffer the consequences," he said.
Why Your Ongoing Support Is Essential
Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support. Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights. Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive. Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most. Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Shares in Bayer took a nosedive on Monday--just days after newly-acquired Monsanto was ordered to pay $289 million in damages to a man who alleged that the company's glyphosate-based herbicides, including the widely used weedkiller Roundup, caused his cancer.
At one point the German pharmaceutical giant's shares fell by as much as 14 percent, Reutersreported, marking a loss in value of roughly $14 billion.
It capped off the U.S. trading day as one of the "biggest losers," ending at a 10-percent loss.
Friday was also a losing day for Monsanto, which Bayer AG controversially acquired for $62.5 billion in June. In a landmark trial, a San Francisco jury unanimously found that the company failed to warn school groundskeeper Dewayne Johnson, who's suffering from non-Hodgkin's lymphoma, and other consumers of the cancer risks from its weed killers, and said the company acted "with malice or oppression."
\u201cWith this verdict and more than 4,000 other plaintiffs waiting in the wings, @MonsantoCo could be in court for decades to come and it could cost them and its new owner, @Bayer, hundreds of millions \u2013 if not billions \u2013 of dollars in damages. #Rounduptrial https://t.co/3ZyGr0eWko\u201d— carey gillam \u270d\ufe0f \ud83d\udcd3 (@carey gillam \u270d\ufe0f \ud83d\udcd3) 1534182010
The International Agency for Research on Cancer (IARC)--a branch of the World Health Organization (WHO)--classified glyphosate as a probable human carcinogen, but Monsanto says its Roundup is safe, and that it plans on appealing.
Monday also marked the last day of the public comment period for the finalization of the merger process, prompting a broad range of advocacy groups to voice their opposition once again.
"No matter how you cut it," said said Daniel Raichel, an attorney with the Nature Program at NRDC, "a Bayer/Monsanto merger spells higher costs for farmers and locks in the chemical-heavy agricultural practices that threaten our health and the bees and other pollinators critical to food security."
"The Department needs to reverse course and block the merger before we all suffer the consequences," he said.
Shares in Bayer took a nosedive on Monday--just days after newly-acquired Monsanto was ordered to pay $289 million in damages to a man who alleged that the company's glyphosate-based herbicides, including the widely used weedkiller Roundup, caused his cancer.
At one point the German pharmaceutical giant's shares fell by as much as 14 percent, Reutersreported, marking a loss in value of roughly $14 billion.
It capped off the U.S. trading day as one of the "biggest losers," ending at a 10-percent loss.
Friday was also a losing day for Monsanto, which Bayer AG controversially acquired for $62.5 billion in June. In a landmark trial, a San Francisco jury unanimously found that the company failed to warn school groundskeeper Dewayne Johnson, who's suffering from non-Hodgkin's lymphoma, and other consumers of the cancer risks from its weed killers, and said the company acted "with malice or oppression."
\u201cWith this verdict and more than 4,000 other plaintiffs waiting in the wings, @MonsantoCo could be in court for decades to come and it could cost them and its new owner, @Bayer, hundreds of millions \u2013 if not billions \u2013 of dollars in damages. #Rounduptrial https://t.co/3ZyGr0eWko\u201d— carey gillam \u270d\ufe0f \ud83d\udcd3 (@carey gillam \u270d\ufe0f \ud83d\udcd3) 1534182010
The International Agency for Research on Cancer (IARC)--a branch of the World Health Organization (WHO)--classified glyphosate as a probable human carcinogen, but Monsanto says its Roundup is safe, and that it plans on appealing.
Monday also marked the last day of the public comment period for the finalization of the merger process, prompting a broad range of advocacy groups to voice their opposition once again.
"No matter how you cut it," said said Daniel Raichel, an attorney with the Nature Program at NRDC, "a Bayer/Monsanto merger spells higher costs for farmers and locks in the chemical-heavy agricultural practices that threaten our health and the bees and other pollinators critical to food security."
"The Department needs to reverse course and block the merger before we all suffer the consequences," he said.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.